


Advanced Instruments to acquire Solentim to expand bioprocess workflows

August 6, 2021 | News

The partnership will expedite commercial and R&D capabilities for advanced therapies through clonal cell line development using AI and automation



Advanced Instruments, a leading manufacturer of analytical instruments and services for bioprocessing is set to acquire UK-based Solentim, a global leader of solutions for the isolation and characterization of high-value single cell clones in cell line development (CLD) applications. The acquisition expands both companies' positions in the bioprocess workflows for advanced therapies.

The partnership will support clonal cell line development with enhanced technical capabilities like imaging, advanced AI capabilities, and automation expertise to expand innovative solutions.

Advanced Instruments' OsmoTECH® portfolio of osmometers, designed specifically for the biopharm industry, is a powerful tool to characterize and optimize cell culture conditions to support clonal growth and selection as well as support upstream and downstream production processes.

The Solentim products are utilized in the early stages of biologic drug development to accelerate the selection of optimal clones for production of monoclonal antibodies, gene therapies and iPSC derived cell therapies. Advanced Instruments' and Solentim's technologies are synergistic, drive efficiencies, and support improved clonal lines for use in therapeutic workflows. Solentim is based in Bournemouth, UK, with additional sites that serve customers in the United States, Europe, and Asia Pacific.

"The addition of Solentim aligns with our core strategy to invest in leading technologies that deliver significant customer value across different segments in monoclonal antibody and cell and gene therapies," commented Byron Selman, President & CEO of Advanced Instruments.